【野村：药明康德第一季度业绩强劲，维持目标价和“买入”评级】 野村发报告称，药明康德2025 年第一季度收入和盈利增长重回两位数水平，订单积压同比增 47%。第一季收入同比增 21%至 965 亿元人民币。按业务部门划分，化学业务收入 73.9 亿元，同比增 32.9%，TIDES 业务收入同比增 187.6%至 22.4 亿元。测试业务销售额同比减 4.9%至 12.9 亿元，生物业务收入 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.